Search results for " Type A"

showing 10 items of 67 documents

Penn classification in acute aortic dissection patients

2016

Objective The objective of this study was to evaluate the effectiveness of the Penn classification in predicting in-hospital mortality after surgery in acute type A aortic dissection patients. Methods We evaluated 58 patients (42 men and 16 women; mean age 62.17 ± 10.6 years) who underwent emergency surgery for acute type A aortic dissection between September 2003 and June 2010 in our department. We investigated the correlation between the pre-operative malperfusion and in-hospital outcome after surgery. Results Twenty-eight patients (48%) were Penn class Aa (absence of branch vessel malperfusion or circulatory collapse), 11 (19%) were Penn class Ab (branch vessel malperfusion with ischaemi…

MaleType A dissection Stanford classification DeBakey classification Penn classificationMyocardial IschemiaRisk AssessmentOutcome Assessment (Health Care)Outcome Assessment Health CarePreoperative CareStanford classificationHumansSettore MED/05 - Patologia ClinicaHospital MortalityAgedType A dissection – Stanford classification – DeBakey classification – Penn classificationPenn classificationSettore MED/23 - Chirurgia CardiacaShockGeneral MedicineMiddle AgedPrognosisAneurysmDeBakey classification; Penn classification; Stanford classification; Type A dissection; Aged; Female; Hospital Mortality; Humans; Italy; Male; Middle Aged; Myocardial Ischemia; Outcome Assessment (Health Care); Preoperative Care; Prognosis; Risk Assessment; Shock; Vascular Surgical Procedures; Aneurysm Dissecting; Aortic AneurysmAortic AneurysmSettore MED/23Aortic DissectionItalyDeBakey classificationType A dissectionFemaleCardiology and Cardiovascular MedicineVascular Surgical ProceduresDissecting
researchProduct

OnabotulinumtoxinA: how deep will it go?

2014

First-line treatment of overactive bladder syndrome (OAB) is based on conservative measures and oral medication such asmuscarinic receptor antagonists and, more recently, b3-adrenoceptor agonists.While this provides effective symptom relief for many patients, for others it has insufficient efficacy and/or intolerable side effects. The potent neurotoxin onabotulinumtoxinA (BoNT-A) has shown efficacy in placebo-controlled trials in patients with neurogenic voiding dysfunction or OAB [1], largely including patients exhibiting an insufficient treatment response to muscarinic antagonists. Although the role of a strong placebo component in the beneficial effects of oral treatment is well known, a…

Malebusiness.industryUrinary Bladder OveractiveUrologyIncidence (epidemiology)Urinary systemAcetylcholine Release InhibitorsPlaceboRefractoryQuality of lifeOral administrationAnesthesiaMedicineHumansFemaleBotulinum Toxins Type AAdverse effectLead (electronics)businessEuropean urology
researchProduct

Botulinum Toxin Type B Blocks Sudomotor Function Effectively: A 6 Month Follow Up

2003

This study analyzes the suppression of sweat gland activity by botulinum toxin type B. We injected botulinum toxin type B (between 2 and 1000 mouse units subcutaneously) in the lateral side of both lower legs in 15 healthy volunteers. Sweat tests were carried out before botulinum toxin type B injections, and at 3 wk, 3 mo, and 6 mo. We studied focal anhidrosis by iodine–starch staining and by capacitance hygrometry after carbachol iontophoresis, according to the quantitative sudomotor axon reflex test (QSART). Iodine starch staining indicated that a threshold dose of 8 mouse units botulinum toxin type B leads to anhidrotic skin spots (>4 cm2) after 3 wk. Duration of anhidrosis was prolonged…

Malemedicine.medical_specialtyCarbacholBotulinum ToxinsSweatingDermatologyBiochemistrySWEATSweat glandInternal medicinemedicineHumansHyperhidrosisAnhidrosisBotulinum Toxins Type AMolecular BiologyHypohidrosisLegIontophoresisStaining and Labelingbusiness.industryHyperhidrosisautonomic nervous systemStarchCell BiologySweat GlandsSudomotorEndocrinologymedicine.anatomical_structureAxon reflexFemalemedicine.symptombusinessiodine starch stainingbotulinum toxin Bmedicine.drugFollow-Up StudiesIodineJournal of Investigative Dermatology
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Approximation of plurisubharmonic functions

2015

We extend a result by Fornaaess and Wiegerinck [Ark. Mat. 1989;27:257-272] on plurisubharmonic Mergelyan type approximation to domains with boundaries locally given by graphs of continuous functions.

Numerical AnalysisPure mathematicsApplied Mathematics010102 general mathematicsMathematical analysista111Type (model theory)01 natural sciences010101 applied mathematicsComputational Mathematicsboundary regularityMergelyan type approximationcontinuous boundaryplurisubharmonic functions0101 mathematicsapproximationAnalysisMathematicsComplex Variables and Elliptic Equations
researchProduct

Reorganization of Nuclear Pore Complexes and the Lamina in Late-Stage Parvovirus Infection

2015

Article

Parvovirus Canineanimal diseasesvirusesnuclear pore complexesImmunologyMicrobiologyParvoviridae InfectionsCapsidDogsVirologymedicineotorhinolaryngologic diseasesAnimalsDog DiseasesNuclear poreparvovovirusCell NucleusNuclear LaminaLamin Type BbiologyParvovirusParvovirus infectionCanine parvovirusLamin Type Abiology.organism_classificationmedicine.diseaseVirologyVirus-Cell InteractionsCell biologyNuclear Pore Complex ProteinsCell nucleusstomatognathic diseasesmedicine.anatomical_structureInsect ScienceNuclear PoreNuclear laminaNucleusLamin
researchProduct

Inhibition in vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening

2012

To search for small molecular size inhibitors of botulinum neurotoxin A (BoNT/A) endopeptidase activity, we have screened the NCI library containing about 1 million structures against the substrate binding pocket of BoNT/A. Virtual screening (VS) was performed with the software Glide (Grid-based ligand docking energetics) and the findings were confirmed by AutoDock. Ten compounds were found that had favorable energetic and glide criteria and 5 of these compounds were selected for their ability to protect mice in vivo against a lethal dose of BoNT/A. Each compound was incubated at different molar excesses with a lethal dose of the toxin and then the mixture injected intravenously into mice. …

Protein ConformationToxinChemistryNeurotoxinsLethal doseComputational BiologyAutoDockPharmacologyProtective AgentsToxicologymedicine.disease_causeSmall moleculeToxicologyMiceEndopeptidase activityDocking (molecular)In vivoToxicitymedicineAnimalsBotulinum Toxins Type ASequence AlignmentSoftwareToxicon
researchProduct

Botulinum toxin in preparation of oral cavity for microsurgical reconstruction.

2010

CONCLUSIONS: Infiltration of botulinum toxin in the major salivary glands allows a temporary reduction of salivation that begins 8 days afterwards and returns to normal within 2 months. The inhibition of salivary secretion, carried out before the oral cavity reconstructive surgery, could allow a reduction of the incidence of oro-cutaneous fistulas and local complications. OBJECTIVES: Saliva stagnation is a risk factor for patients who have to undergo reconstructive microsurgery of the oral cavity, because of fistula formation and local complications in the oral cavity. The authors suggest infiltration of botulinum toxin in the major salivary glands to reduce salivation temporarily during th…

SalivaReconstructive surgerymedicine.medical_specialtyMicrosurgeryBotulinum Toxins Type A/administration & dosage* Humans Microsurgery* Mouth Floor/surgery Mouth Neoplasms/surgery* Neck Dissection Neoplasm Invasiveness Preoperative Care* Salivary Glands/drug effects* Salivation/drug effects Surgical Flaps Tongue Neoplasms/surgeryFistulamedicine.medical_treatmentSalivary GlandsSurgical FlapsMajor Salivary GlandPreoperative CareMedicineHumansOral Cavity CarcinomaNeoplasm InvasivenessBotulinum Toxins Type AMouth Floorbusiness.industryGeneral MedicineMicrosurgerymedicine.diseaseBotulinum toxinSurgeryTongue NeoplasmsOtorhinolaryngologyNeck DissectionMouth NeoplasmsbusinessComplicationSalivationmedicine.drugActa oto-laryngologica
researchProduct

Visual field defects,type A personality,anxiety and coping styles in patients with primary open angle Glaucoma

2012

Settore MED/30 - Malattie Apparato VisivoVisual field defects type A personalityanxiety coping style primary open angle Glaucoma
researchProduct

Functional characterisation of the first HSP110 inhibitors.

2023

Heat shock proteins are molecular chaperones highly expressed in haematological malignancies. My laboratory has shown that the heat shock protein HSP110 is a new and important therapeutic target In colorectal cancer and in non-Hodgkin's lymphoma. As there were no existing inhibitors of HSP110, a screening strategy of a chemical library was carried out and allowed the identification of two molecules capable of specifically inhibiting the chaperone activity of HSP110. My thesis objective was to characterise and functionally validate these newly identified molecules in diffuse large cell B lymphomas. I have shown that one of these molecules limits the interaction of HSP110 with the SYK signall…

Signaling pathwaysVoies de signalisationHeat Shock Protein[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyProtéine de choc thermiqueTargeted therapyActivated B Cell Diffuse Large B-Cell LymphomaLymphome B Diffus à Grandes Cellules de Type ActivéLymphome B Primitif du MédiastinCancer treatment[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Primary Mediastinal B cell LymphomaThérapie cibléeTraitements du cancer
researchProduct